Holen Sie sich die Stockscreener-App
19.47
2.84%
-0.57
Schlusskurs vom Vortag:
$20.04
Offen:
$20.25
24-Stunden-Volumen:
1.84M
Relative Volume:
0.78
Marktkapitalisierung:
$2.45B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-9.5911
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
+0.15%
1M Leistung:
+9.63%
6M Leistung:
-34.96%
1J Leistung:
-48.70%
1-Tages-Spanne:
$19.23
$20.44
1-Wochen-Bereich:
$19.13
$20.61
52-Wochen-Spanne:
$16.10
$41.94
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
19.47 | 2.44B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals Inc. Stock Analysis and ForecastFree Investment Risk Control - Jammu Links News
What analysts say about Apellis Pharmaceuticals Inc. stockHigh-octane gains - Jammu Links News
What drives Apellis Pharmaceuticals Inc. stock priceFast-track wealth growth - Jammu Links News
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga
Is Apellis Pharmaceuticals Inc. a good long term investmentExceptional profit margins - Jammu Links News
Fierce Biotech Layoff Tracker 2025: Sarepta lays off 500 staffers; GSK trims R&D team - Fierce Biotech
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times
Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan
H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada
How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com
Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN
Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail
16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - Insider Monkey
Apellis stock surges after Sobi $300 million royalty deal - MSN
Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing - MSN
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
WilmerHale Advises Apellis Pharmaceuticals in Purchase Agreement with Sobi - WilmerHale
(APLS) Trading Advice - news.stocktradersdaily.com
Apellis signs royalty purchase deal with Sobi for Aspaveli - MSN
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - MSN
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq
Mizuho maintains Neutral rating on Apellis stock amid royalty deal with Sobi - Investing.com Canada
Apellis to receive $300 million in royalty deal with Sobi By Investing.com - Investing.com South Africa
Apellis to receive $300 million in royalty deal with Sobi - Investing.com India
Apellis Pharmaceuticals enters $275 million royalty agreement with Sobi By Investing.com - Investing.com UK
Eylea Market Future Business Opportunities 2025-2032 | Bayer AG, Bausch + Lomb, Apellis Pharmaceuticals - openPR.com
Apellis Pharma general counsel Watson sells $93k in stock By Investing.com - Investing.com Canada
Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.
How To Trade (APLS) - news.stocktradersdaily.com
Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth - Investing.com
Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth By Investing.com - Investing.com Nigeria
Transcript : Apellis Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - MSN
Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN - Yahoo
Wealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study - Yahoo Finance
Apellis Pharmaceuticals (APLS) Reports Promising Phase 3 Study R - GuruFocus
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Susta - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Promising Empaveli Data - GuruFocus
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? - Yahoo Finance
Sobi and Apellis data underscore Aspaveli potential - The Pharma Letter
Apellis Pharmaceuticals, Inc. and Sobi Announce EMPAVELI®? (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - MarketScreener
Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study - MarketScreener
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - The Manila Times
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Apellis Pharmaceuticals Inc-Aktie (APLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Francois Cedric | Chief Executive Officer |
Jul 17 '25 |
Sale |
20.21 |
19,725 |
398,735 |
331,605 |
| Watson David O. | General Counsel |
Jul 16 '25 |
Sale |
19.55 |
5,000 |
97,750 |
128,730 |
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):